Shaping Therapeutic Development with Cutting-Edge CRISPR Nucleases
This live webinar recording explores Synthego’s cutting-edge nuclease portfolio, featuring our newest engineered nuclease, eSpOT-ON. Casey Jowdy, Senior Product Manager at Synthego, dives into its development, how its on-target and off-target profile (fidelity) compares to other Cas9 variants, and demonstrates its therapeutic potential by treating familial hypercholesterolemia. Through detailed data analysis, you will gain a deeper understanding of how eSpOT-ON enhances genome editing efficiency and how you can start using it in your work today.